Literature DB >> 20164492

Rasagiline in Parkinson's disease.

Moussa B H Youdim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20164492     DOI： 10.1056/NEJMc0910491

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Discordant effects of rasagiline doses in Parkinson disease.

Authors:  Spyros N Deftereos; Christos A Andronis
Journal:  Nat Rev Neurol       Date:  2010-07       Impact factor: 42.937

2.  Tapping natural reservoirs of homing endonucleases for targeted gene modification.

Authors:  Ryo Takeuchi; Abigail R Lambert; Amanda Nga-Sze Mak; Kyle Jacoby; Russell J Dickson; Gregory B Gloor; Andrew M Scharenberg; David R Edgell; Barry L Stoddard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-22       Impact factor: 11.205

3.  MAO-inhibitors in Parkinson's Disease.

Authors:  Peter Riederer; Gerd Laux
Journal:  Exp Neurobiol       Date:  2011-03-31       Impact factor: 3.261

4.  Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease.

Authors:  Kay Cheong Teo; Shu-Leong Ho
Journal:  Transl Neurodegener       Date:  2013-09-08       Impact factor: 8.014

Review 5.  Neuroprotection in Parkinson's disease: facts and hopes.

Authors:  András Salamon; Dénes Zádori; László Szpisjak; Péter Klivényi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2019-12-11       Impact factor: 3.575
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.